10-QPeriod: Q3 FY2024

CARDINAL HEALTH INC Quarterly Report for Q3 Ended Mar 31, 2024

Filed May 2, 2024For Securities:CAH

Summary

Cardinal Health Inc. reported solid revenue growth in the third quarter of fiscal year 2024, with total revenue increasing by 9% year-over-year to $54.9 billion. This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical and Specialty Solutions segment. While GAAP operating earnings saw a decline primarily due to litigation charges and goodwill impairment, the company's non-GAAP operating earnings showed significant improvement, increasing by 10% to $666 million. This highlights the company's operational performance excluding certain non-recurring or significant charges. Despite ongoing challenges, including significant litigation expenses and a goodwill impairment charge related to the GMPD segment, Cardinal Health demonstrated strong operational execution. The company's strategic acquisition of Specialty Networks for $1.2 billion aims to enhance its data analytics capabilities and expand its offerings in key therapeutic areas. However, investors should note the upcoming non-renewal of contracts with OptumRx, which represented 16% of fiscal year 2023 revenue, posing a significant headwind for fiscal year 2025. The company is actively managing its capital through share repurchases and dividends while maintaining adequate liquidity.

Financial Highlights

49 data points
Beta

Revenue

$54.87B

3.5% Gross Margin

Net Income

$261.00M

0.5% Net Margin

EPS (Diluted)

$1.07

Total Assets

$45.88B

Cash & Equivalents

$3.75B

Free Cash Flow

-$139.00M

Financial Statements
Beta
Revenue$54.87B
Cost of Revenue$52.93B
Gross Profit$1.94B
SG&A Expenses$1.27B
Operating Income$369.00M
Interest Expense$28.00M
Net Income$261.00M
EPS (Basic)$1.07
EPS (Diluted)$1.07
Shares Outstanding (Basic)243.00M
Shares Outstanding (Diluted)245.00M

Key Highlights

  • 1Revenue increased by 9% to $54.9 billion for the three months ended March 31, 2024, driven by the Pharmaceutical and Specialty Solutions segment.
  • 2Non-GAAP operating earnings grew by 10% to $666 million for the quarter, indicating improved underlying business performance.
  • 3GAAP operating earnings decreased by 36% to $367 million, largely impacted by litigation charges and a $90 million goodwill impairment.
  • 4Acquisition of Specialty Networks for $1.2 billion completed in March 2024 to expand data analytics and biopharma offerings.
  • 5Significant impact from the upcoming non-renewal of pharmaceutical distribution contracts with OptumRx, which accounted for 16% of FY2023 revenue, expected to impact FY2025 results.
  • 6Cash and equivalents stood at $3.7 billion, with $1.7 billion in net cash provided by operating activities for the nine months ended March 31, 2024.
  • 7The company returned $750 million to shareholders through share repurchases and paid $377 million in dividends during the nine months ended March 31, 2024.

Frequently Asked Questions

The non-renewal of pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, is expected to adversely impact Cardinal Health's results of operations, including segment profit, financial condition, and cash flows, particularly in fiscal year 2025. This is due to OptumRx representing 16% of consolidated revenue in fiscal year 2023, and the unwinding of negative net working capital associated with these contracts.

Both litigation charges and goodwill impairments significantly impacted GAAP operating earnings and EPS. For the three months ended March 31, 2024, litigation charges of $193 million (partially offset by a benefit) and a $90 million goodwill impairment charge related to the GMPD segment were recognized. These items, along with others, are excluded from non-GAAP operating earnings, which showed a 10% increase.

The acquisition of Specialty Networks for $1.2 billion is intended to expand Cardinal Health's offerings in key therapeutic areas, accelerate upstream data and research opportunities with biopharma manufacturers, and create a platform for further expansion. Specialty Networks utilizes AI and data analytics to provide insights for independent specialty providers.

As of March 31, 2024, Cardinal Health had $3.7 billion in cash and equivalents. For the nine months ended March 31, 2024, the company generated $1.7 billion in net cash from operating activities. The company also has access to a $2.0 billion commercial paper program and a $2.0 billion revolving credit facility, with no amounts outstanding under these facilities as of the reporting date. Capital was deployed for the Specialty Networks acquisition, share repurchases, and dividends.